Sign in
Taking people in United StatesNo phase

Looking for early leukemia changes in newborn umbilical cord blood

Studies cord blood from children who later develop acute leukemia, to find early changes.

Key facts

Who runs it
Children's Oncology Group
Where
Minneapolis, United StatesSee the site
Trial code
Registry title
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
Status
Recruiting
People taking part
300 people, planned
Started
25 Aug 2021
Planned end
30 Sept 2026
Type of study
Observational
Treatments tested
  • Cord blood Sample Collection
  • Case identification and recruitment
  • Questionnaire Administration
Record updated
8 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) whose cord blood was stored at birth.

Age
Up to 25 years old at the time of the first leukemia diagnosis.
Sex
All sexes can join.
Disease stage
Diagnosis of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Earlier treatment
Stored leukemia samples taken before treatment, at diagnosis, must be available.

Main reasons for not taking part

  • Cord blood was not stored at birth.
  • No stored pre-treatment leukemia samples at the COG Biopathology Center or the treating institution.

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • The patient must have a diagnosis of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML)
  • Stored diagnostic pre-treatment samples corresponding to the patient's original diagnosis of leukemia must be available for request from either the COG Biopathology Center or a treating institution
  • The patient must be enrolled on APEC14B1 with consent to future contact and indicate that cord blood was stored at birth in the APEC14B1 registry intake data
  • The patient must also have been registered with COG by a North American (limited to the U.S. and Canada) member institution
  • ≤ 25 years old at the time of original diagnosis with ALL or AML
  • The patient must be able to understand written and spoken English or Spanish
  • All patients must provide their consent/assent, as appropriate, and for patients under the age of majority at least one parent or legal guardian must provide consent as well
  • All institutional, FDA, and NCI requirements for human studies must be met

Who cannot take part

  • Patients who responded that cord blood was not stored at birth are excluded. Patients without stored diagnostic, pre-treatment leukemia samples at either the COG Biopathology Center or their treating institution are excluded

Where in United States

  • University of Minnesota/Masonic Cancer CenterMinneapolis, United StatesContact: Logan Spector, PhDTaking people

About the trial

What the trial wants to find out

A comprehensive mechanistic and epidemiological study to obtain banked cord blood samples from consecutive childhood leukemia patients enrolled in the COG Project:EveryChild (APEC14B1) study. Will attempt to backtrack the initiating genomic alteration identified in the matched diagnostic leukemia sample and molecularly characterize pre-leukemic cells. The ultimate goal of this research is to pinpoint the cell of origin of leukemogenic alterations formed in utero, elucidating the etiology of these initiating mutations (as opposed to frank leukemia), and devising a test for circulating pre-leukemia that can be applied on a population-wide basis.

The group in the trial

  • Ancillary-Correlative (Cord Blood collection)

    Accrue patients with ALL and AML who indicate having banked cord blood at birth through the COG Project:EveryChild (APEC14B1)

    Treatment: Cord blood Sample Collection, Case identification and recruitment, and Questionnaire Administration

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
Plain-language title
Looking for early leukemia changes in newborn umbilical cord bloodGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
8 April 2026